Ampersand Closes Fund X

Ampersand Capital Partners has closed its latest fund, Ampersand 2020 LP (AMP-20) with $690 million in limited partner commitments. The new fund – Ampersand’s tenth fund since 1992 – was oversubscribed and closed after just three months of fundraising.

Limited partners in the new fund include a global set of institutional investors including endowments, foundations, pension plans, insurance companies, fund of funds and family offices.

Ampersand makes majority or minority equity investments in healthcare-related companies that have from $10 million to $100 million of revenue. Ampersand is typically the first institutional investor in founder-owned businesses.  Sectors of specific interest within healthcare include laboratory services; laboratory products; contract manufacturing; pharmaceutical services; specialty pharmaceuticals; and healthcare services.

“We greatly appreciate the strong support from both existing and new investors, and their confidence in Ampersand’s differentiated healthcare investment strategy which we have executed over multiple market cycles,” said Herb Hooper, managing partner at Ampersand.

Ampersand was founded in 1988 and has offices in the Boston suburb of Wellesley, Massachusetts and in Amsterdam, Netherlands.

Goodwin Procter provided legal services to Ampersand